1. Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis.
- Author
-
Schepers, Melissa, Paes, Dean, Tiane, Assia, Rombaut, Ben, Piccart, Elisabeth, van Veggel, Lieve, Gervois, Pascal, Wolfs, Esther, Lambrichts, Ivo, Brullo, Chiara, Bruno, Olga, Fedele, Ernesto, Ricciarelli, Roberta, ffrench-Constant, Charles, Bechler, Marie E., van Schaik, Pauline, Baron, Wia, Lefevere, Evy, Wasner, Kobi, and Grünewald, Anne
- Subjects
- *
MYELIN sheath diseases , *MULTIPLE sclerosis , *MYELIN oligodendrocyte glycoprotein , *CYCLIC adenylic acid , *CENTRAL nervous system diseases , *MYELIN , *VISUAL evoked potentials - Abstract
[Display omitted] • Selective inhibition of PDE4 gene products and isoforms provides new opportunities in the PDE4 inhibition field, especially for MS. • Selective PDE4B inhibition suppresses inflammatory responses by phagocytes. • PDE4D, but not PDE4B inhibition promotes oligodendrocyte differentiation and thus enhances remyelination. • The therapeutic dose of the applied PDE4B and PDE4D inhibitors does not induce emetic side effects. • PDE4D isoform fingerprints in human area postrema neurons and MS lesions reveal novel targets to stimulate remyelination while avoiding emesis. Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by focal inflammatory lesions and prominent demyelination. Even though the currently available therapies are effective in treating the initial stages of disease, they are unable to halt or reverse disease progression into the chronic progressive stage. Thus far, no repair-inducing treatments are available for progressive MS patients. Hence, there is an urgent need for the development of new therapeutic strategies either targeting the destructive immunological demyelination or boosting endogenous repair mechanisms. Using in vitro , ex vivo, and in vivo models, we demonstrate that selective inhibition of phosphodiesterase 4 (PDE4), a family of enzymes that hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP), reduces inflammation and promotes myelin repair. More specifically, we segregated the myelination-promoting and anti-inflammatory effects into a PDE4D- and PDE4B-dependent process respectively. We show that inhibition of PDE4D boosts oligodendrocyte progenitor cells (OPC) differentiation and enhances (re)myelination of both murine OPCs and human iPSC-derived OPCs. In addition, PDE4D inhibition promotes in vivo remyelination in the cuprizone model, which is accompanied by improved spatial memory and reduced visual evoked potential latency times. We further identified that PDE4B-specific inhibition exerts anti-inflammatory effects since it lowers in vitro monocytic nitric oxide (NO) production and improves in vivo neurological scores during the early phase of experimental autoimmune encephalomyelitis (EAE). In contrast to the pan PDE4 inhibitor roflumilast, the therapeutic dose of both the PDE4B-specific inhibitor A33 and the PDE4D-specific inhibitor Gebr32a did not trigger emesis-like side effects in rodents. Finally, we report distinct PDE4D isoform expression patterns in human area postrema neurons and human oligodendroglia lineage cells. Using the CRISPR-Cas9 system, we confirmed that pde4d1/2 and pde4d6 are the key targets to induce OPC differentiation. Collectively, these data demonstrate that gene specific PDE4 inhibitors have potential as novel therapeutic agents for targeting the distinct disease processes of MS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF